Parameters | Group A | Group B | P value |
---|---|---|---|
 | (MMC+Gemcitabine) | (MMC) |  |
Total patients | 102 | 96 | NS+ |
Male | 81 | 78 | NS+ |
Female | 21 | 19 | NS+ |
Age | 65.7±9.8 yrs | 63.9±8.9 yrs | NS+ |
Mean Duration of follow up | 36 months | 36 months | Â |
Mean size of tumor <2cm | 63 | 58 | NS+ |
Mean sixe of tume >2 cm | 39 | 38 | NS+ |
Stage Ta | 60 | 58 | NS+ |
Stage T1 | 42 | 38 | NS+ |
Grade 1 | 19 | 17 | NS+ |
Grade 2 | 63 | 61 | NS+ |
Grade 3 | 20 | 18 | NS+ |
Previous treatment with BCG | All | All | Â |
Aim of complete response | 100% | 100% | Â |
Actual complete response | 83.67% (82) | 65.6% (63) | 0.001* |
Recurrence % | 12.2% (12) | 25.3% (16) | 0.001* |
Recurrence | 22±6.16 months | 14.5±8.26 months | 0.001* |
Recurrence range in months | 8-36 months | 4-14 months | Â |